AbbVie Inc. (ABBV) is set to report its third-quarter earnings on Wednesday, with analysts expecting strong results. The company recently acquired Aliada Therapeutics, bolstering its Alzheimer’s research portfolio. We analyze AbbVie’s technical setup and analyst forecasts to see what lies ahead for the stock.
Eli Lilly and Company (LLY) is set to release its third-quarter earnings on Wednesday, with Wall Street expecting strong performance driven by the company’s successful weight loss drugs. While the stock has experienced significant growth, technical indicators currently suggest a bearish outlook. However, analyst ratings and potential oversold status point towards a possible bullish recovery. This article analyzes the company’s earnings expectations, technical analysis, and analyst sentiments to provide a comprehensive outlook on Eli Lilly’s stock performance.
Corcept Therapeutics (CORT) is set to release its quarterly earnings on October 30th. This article provides a comprehensive analysis of the company’s past performance, analyst expectations, and peer comparisons, highlighting key metrics to watch for during the earnings call.
Novartis AG (NVS) exceeded analyst estimates in the third quarter, reporting a 9% increase in sales to $12.823 billion, driven by strong performance across key growth drivers. The company also raised its full-year guidance, reflecting its confidence in continued momentum. Notable highlights include the successful launch of new indications for Kisqali and Fabhalta, and the growth of Cosentyx, Entresto, and Kesimpta.
Pfizer exceeded analysts’ expectations for the third quarter, fueled by robust sales of Paxlovid and growth across its portfolio. The company also raised its revenue and earnings forecasts for the year, reflecting strong demand for its COVID-19 treatments and other key products.
Monopar Therapeutics (MNPR) shares are experiencing a sharp decline on Friday after gaining on Thursday, following the company’s licensing agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, a potential treatment for Wilson disease. While the drug has shown promise in a Phase 3 clinical trial, its development was previously halted due to Phase 2 data and regulatory concerns. Monopar will now lead the development and commercialization efforts.
Sanofi SA reported impressive third-quarter results, exceeding analysts’ expectations with strong sales growth fueled by its blockbuster eczema drug Dupixent, new pharmaceutical launches, and vaccine performance. The company also provided an updated outlook for 2024, reaffirming its confidence in Dupixent’s continued success and anticipating strong growth in vaccine sales.
Cybin Inc. has received a US patent for its CYB005 phenethylamines program, which focuses on developing non-hallucinogenic molecules for Central Nervous System (CNS) disorders. This patent further strengthens Cybin’s commitment to research beyond its clinical tryptamine programs and highlights the potential of non-hallucinogenic 5-HT receptor agonists for treating CNS disorders. The company continues to progress with its clinical-stage psychiatry programs, CYB003 and CYB004, for major depressive disorder and Generalized Anxiety Disorder, respectively.
Alto Neuroscience, Inc. (ANRO) announced disappointing results from its Phase 2b trial of ALTO-100 for major depressive disorder (MDD), leading to a significant drop in the company’s stock price. Despite the setback, Alto remains optimistic about its biomarker-driven approach and its other ongoing clinical trials.
Activist investor Starboard Value has sharply criticized Pfizer, accusing the pharmaceutical giant of failing to deliver on its promises of innovation and growth. Starboard argues that Pfizer’s leadership has not capitalized on the momentum following the COVID-19 pandemic, resulting in underperformance in research and development (R&D) and mergers and acquisitions (M&A). The investor highlights the company’s missed targets, inflated acquisitions, and lagging returns on investments, calling for the board to hold management accountable.
